Loading...
•
Sep 30, 2024
CRISPR Therapeutics Q3 2024 Earnings Report
Reported financial results for the third quarter ended September 30, 2024.
Key Takeaways
CRISPR Therapeutics reported a net loss of $85.9 million for the third quarter of 2024, compared to a net loss of $112.2 million for the third quarter of 2023. The company's cash, cash equivalents, and marketable securities were $1,935.6 million as of September 30, 2024.
CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada.
45 authorized treatment centers (ATCs) activated globally for CASGEVY and approximately 40 patients have had cells collected across all regions as of mid-October.
Two clinical trials are ongoing for next generation CAR T product candidate, CTX112™ targeting CD19, in B-cell malignancies and systemic lupus erythematosus.
Strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities as of September 30, 2024.
Forward Guidance
The company anticipates several important data catalysts over the next 9-12 months as it advances its portfolio.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...